CN116539572A - Drug sensitive detection system convenient for recording growth condition of tumor cells - Google Patents
Drug sensitive detection system convenient for recording growth condition of tumor cells Download PDFInfo
- Publication number
- CN116539572A CN116539572A CN202310315431.6A CN202310315431A CN116539572A CN 116539572 A CN116539572 A CN 116539572A CN 202310315431 A CN202310315431 A CN 202310315431A CN 116539572 A CN116539572 A CN 116539572A
- Authority
- CN
- China
- Prior art keywords
- tumor
- drug
- cells
- detection
- tumor sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 101
- 229940079593 drug Drugs 0.000 title claims abstract description 84
- 210000004881 tumor cell Anatomy 0.000 title claims abstract description 30
- 230000012010 growth Effects 0.000 title claims abstract description 20
- 238000011896 sensitive detection Methods 0.000 title claims abstract description 15
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 173
- 210000004027 cell Anatomy 0.000 claims abstract description 81
- 238000001514 detection method Methods 0.000 claims abstract description 62
- 238000003125 immunofluorescent labeling Methods 0.000 claims abstract description 36
- 230000005764 inhibitory process Effects 0.000 claims abstract description 21
- 239000007788 liquid Substances 0.000 claims abstract description 19
- 238000012377 drug delivery Methods 0.000 claims abstract description 9
- 238000010186 staining Methods 0.000 claims abstract description 8
- 230000035945 sensitivity Effects 0.000 claims description 19
- 238000001647 drug administration Methods 0.000 claims description 17
- 238000012757 fluorescence staining Methods 0.000 claims description 14
- 230000004044 response Effects 0.000 claims description 9
- 230000004083 survival effect Effects 0.000 claims description 9
- 230000004614 tumor growth Effects 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 7
- 238000002512 chemotherapy Methods 0.000 claims description 6
- 238000011254 conventional chemotherapy Methods 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 238000005070 sampling Methods 0.000 claims description 4
- 238000012360 testing method Methods 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 238000001574 biopsy Methods 0.000 claims description 3
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 3
- 231100000673 dose–response relationship Toxicity 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 3
- -1 polydimethylsiloxane Polymers 0.000 claims description 3
- 230000009467 reduction Effects 0.000 claims description 3
- 238000003556 assay Methods 0.000 claims 8
- 238000001727 in vivo Methods 0.000 claims 1
- 239000007850 fluorescent dye Substances 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 description 34
- 201000011510 cancer Diseases 0.000 description 8
- 230000000694 effects Effects 0.000 description 4
- 230000009471 action Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000004043 dyeing Methods 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 238000010166 immunofluorescence Methods 0.000 description 3
- 201000009030 Carcinoma Diseases 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000003313 weakening effect Effects 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/84—Systems specially adapted for particular applications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Abstract
The invention discloses a drug sensitive detection system convenient for recording the growth condition of tumor cells, which comprises a tumor sample, a 3D micro-fluidic chip, a drug delivery system and an immunofluorescence staining system, wherein the 3D micro-fluidic chip comprises a 3D micro-fluidic detection system, a cell/tissue culture chamber and a liquid flow system. The drug sensitive detection system convenient for recording the growth condition of the tumor cells is provided with an immunofluorescence staining system, living cells in the tumor samples can be marked through the immunofluorescence staining system, marked images of the living cells in the tumor samples can be recorded and presented through the image detection system in the immunofluorescence staining system, the number of living cells of the tumor tissues and the dynamic inhibition rate of tumor drugs to the tumor can be obtained through observing the staining condition of the immunofluorescence staining system on the tumor samples and the depth of fluorescent staining, so that the growth condition of the tumor sample cells can be conveniently observed and recorded by staff, and effective guidance is provided for clinical tumor treatment.
Description
Technical Field
The invention relates to the technical field of tumor cell drug sensitivity detection, in particular to a drug sensitivity detection system convenient for recording the growth condition of tumor cells.
Background
Tumors refer to new organisms formed by local tissue cell proliferation under the action of various tumorigenic factors, because the new organisms are more in the form of occupying massive protrusions, also called neoplasms). Liver cancer and pancreatic cancer are both called "cancer king", and are tumors with extremely high malignancy.
According to the cell characteristics of the new organism and the degree of harm to the organism, tumors are classified into benign tumors and malignant tumors. Malignant tumors can be classified into carcinoma and sarcoma, and carcinoma refers to malignant tumors derived from epithelial tissues. Sarcoma refers to malignant tumors of mesenchymal tissues including fibrous connective tissues, fat, muscle, vascular, bone, cartilage tissues and the like, such as malignant tumors formed by large intestine mucosal epithelium, which are called large intestine mucosal epithelium cancer, for short, colorectal cancer.
The individual treatment of tumor is a trend, and has important application value in detecting the sensitivity of the tumor tissue of the patient in vitro.
The utility model provides a tumour cell medicine sensitive detection device of publication number CN202903661U, including detection device body, box body lid, camera, display screen, control management device, slide shaft, medicine detection hole, first layer detection box body, second floor detection box body, fluorescent tube and receiver, monitor each measured medicine cultivation time and state through camera device, send radio signal to the receiver through control system, its convenient operation, real-time control, work efficiency is high and the testing result is accurate. However, the device has certain defects;
1. when the survival state of the tumor cells is observed through the camera device, the activity of the tumor cells cannot be accurately distinguished, the activity of the tumor cells is possibly weakened gradually under the action of the medicine, the weakening amplitude is not easily observed, so that the detection result of the drug resistance of the tumor cells to the medicine is not accurate enough, and the detection result is difficult to effectively guide clinically.
Therefore, we propose a drug sensitive detection system that facilitates recording the growth of tumor cells in order to solve the above-mentioned problems.
Disclosure of Invention
The invention aims to provide a drug sensitive detection system convenient for recording the growth condition of tumor cells, so as to solve the problems that when the existing tumor cell drug sensitive detection device in the current market provided by the background technology observes the survival state of tumor cells through a camera device, the activity of the tumor cells cannot be accurately distinguished, the activity of the tumor cells is possibly weakened gradually under the action of a drug, the weakening amplitude is not easily observed, and therefore, the detection result of the drug resistance of the tumor cells to the drug is not accurate enough, and the detection result is difficult to effectively guide clinically.
In order to achieve the above purpose, the present invention provides the following technical solutions: the utility model provides a drug sensitive detecting system convenient to record tumour cell growth condition, includes tumour sample, 3D micro-fluidic chip, system of dosing and immunofluorescence dyeing system, 3D micro-fluidic chip includes 3D micro-fluidic detecting system, cell/tissue culture room and liquid flow system, and 3D micro-fluidic chip is connected with system of dosing and immunofluorescence dyeing system, and including image software system in the immunofluorescence dyeing system.
Preferably, the cell/tissue culture chamber in the 3D microfluidic chip is communicated with the liquid flow system, the pipeline connected with the cell/tissue culture chamber is millimeter-sized, and a micro valve is introduced into the 3D microfluidic chip, so that the automatic planting of tumor tissues can be realized in a liquid flow mode of the liquid flow system, and the micro valve plays a role in controlling the flow of the liquid flow system, so that adjacent cell/tissue culture chambers are not affected when the tumor samples are cultured and detected, and the drug sensitivity detection precision of the tumor samples is improved.
Preferably, the 3D microfluidic chip adopts an internationally universal polydimethylsiloxane material to construct a three-layer superposition structure, so that a tumor sample can be ensured to be in a liquid flow system similar to that in a body, and subsequent administration and detection are facilitated.
Preferably, the tumor samples can be classified according to the age of the patient, the selected tumor samples are not treated by chemotherapy or other medicaments, and the same tumor sample is sampled at multiple points, so that the accuracy of drug sensitivity detection of the tumor samples is improved, and the sporadic occurrence during detection is avoided.
Preferably, the 3D microfluidic detection system can realize automatic cutting and automatic loading and loading of tumor samples, the tumor samples are automatically cut by the 3D microfluidic detection system to obtain micro tissue blocks with the size of (1 x0.5 mm), and then the tissue blocks are automatically loaded and loaded to a cell/tissue culture chamber at the bottom layer of the 3D microfluidic chip for culture, so that the growth condition of the tumor samples in the 3D microfluidic chip can be observed later.
Preferably, the drug delivery system comprises drug treatment, wherein the drug treatment carries out combination classification on conventional chemotherapy scheme drugs, and sequentially carries out drug delivery treatment on tumor samples, and meanwhile, the drug dosage can be referred to normal clinical treatment dosage, so that in the subsequent treatment process of tumors, the normal clinical treatment dosage can realize the inhibition of the tumors, and meanwhile, a non-drug addition group is arranged to detect the number of living cells and dead cells.
Preferably, the immunofluorescence staining system can label living cells in a tumor sample, so that the cell quantity in the original tumor sample is compared, the dead cell quantity in the tumor sample can be obtained, and the dynamic inhibition rate of the used tumor drug to the tumor is detected.
Preferably, the immunofluorescence staining system comprises an image software system, the image detection system can record a marked image of living cells in a tumor sample, the marked image is presented through the image display system, the number of living cells of tumor tissue and the dynamic inhibition rate of tumor drugs on tumors are obtained by observing the staining condition of the immunofluorescence staining system on the tumor sample and the fluorescence staining depth, the fluorescence staining depth represents the fluorescence intensity and the fluorescence intensity represents the survival state of the living cells in the tumor sample, and therefore, the staff can observe and record the growth condition of the cells of the tumor sample conveniently.
Preferably, the workflow of the drug sensitive detection system is as follows:
s1, collecting tumor samples of surgical excision or biopsy in a tumor patient, wherein the tumor samples can be classified according to the age of the patient, the selected tumor samples are not treated by chemotherapy or other medicaments, multipoint sampling is carried out on the same tumor sample, the accuracy of drug sensitivity detection of the tumor samples is improved, and sporadic occurrence during detection is avoided;
s2, automatically cutting and loading a tumor sample through a 3D micro-fluidic detection system, automatically cutting the tumor sample through the 3D micro-fluidic detection system to obtain a micro tissue block with the size of (1 x0.5 mm), automatically loading and loading the tissue block into a bottom cell/tissue culture chamber of the 3D micro-fluidic chip for culture, and then carrying out drug administration on the 3D micro-fluidic chip through a drug administration system, wherein drug administration is required to carry out drug treatment, the drug treatment carries out combination classification on the conventional chemotherapy scheme drugs, the tumor sample is sequentially subjected to drug administration treatment, and meanwhile, the drug dosage can refer to normal clinical treatment dosage, so that in the follow-up treatment process of tumors, the normal clinical treatment dosage can realize tumor inhibition, and meanwhile, a non-drug administration group is arranged to detect the number of living cells and dead cells;
s3, marking living cells in the tumor sample through an immunofluorescence staining system, recording a marked image of the living cells in the tumor sample through an image detection system in the immunofluorescence staining system, and displaying through an image display system, and obtaining the number of the living cells of the tumor tissue and the dynamic inhibition rate of a tumor drug to the tumor by observing the staining condition of the immunofluorescence staining system on the tumor sample and the fluorescence staining depth, wherein the fluorescence staining depth represents the fluorescence intensity and the fluorescence intensity represents the survival state of the living cells in the tumor sample, so that the staff can observe and record the growth condition of the cells of the tumor sample conveniently;
s4, analyzing according to data presented by an immunofluorescence staining system, setting the inhibition rate of a medicine sieve for 3 days as a main end point of a clinical test, drawing a dose response curve according to the inhibition rate among different groups (age, histological typing and pre-operation stage), scoring according to the area under the curve AUC (the dose which leads to the reduction of the total surviving cell fraction by more than or equal to 35%), indicating that tumor tissues are more sensitive to a therapeutic medicine, classifying the tumor tissues into quick response, having response or no response according to the AUC value, comparing the drug sensitivity detection result with the experience of a clinician, checking whether the detection result is consistent, and judging the authenticity of the drug sensitivity detection result.
Compared with the prior art, the invention has the beneficial effects that: the drug sensitive detection system convenient for recording the growth condition of tumor cells comprises:
1. the method is provided with an immunofluorescence staining system, living cells in a tumor sample can be marked through the immunofluorescence staining system, a marked image of the living cells in the tumor sample can be recorded through an image detection system in the immunofluorescence staining system, and the marked image is presented through an image display system, so that the number of living cells of tumor tissues and the dynamic inhibition rate of tumor drugs on tumors are obtained by observing the staining condition of the immunofluorescence staining system on the tumor sample and the fluorescence staining depth, the fluorescence staining depth represents the fluorescence intensity and the fluorescence intensity represents the survival state of the living cells in the tumor sample, thereby being convenient for staff to observe and record the growth condition of the cells of the tumor sample, and recording the drug sensitivity of the cells of the tumor sample on detection drugs, thereby providing effective guidance for clinical tumor treatment.
Drawings
FIG. 1 is a schematic diagram of the flow structure of a drug sensitive detection system of the present invention;
FIG. 2 is a schematic diagram of the structure of a 3D microfluidic chip according to the present invention;
FIG. 3 is a schematic diagram of an image software system according to the present invention;
FIG. 4 is a schematic representation of clinical therapeutic metering of chemotherapeutic agents according to the present invention.
Detailed Description
The following description of the embodiments of the present invention will be made clearly and completely with reference to the accompanying drawings, in which it is apparent that the embodiments described are only some embodiments of the present invention, but not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
Referring to fig. 1-4, the present invention provides a technical solution: a drug sensitive detection system convenient for recording the growth condition of tumor cells comprises a tumor sample, a 3D micro-fluidic chip, a drug delivery system and an immunofluorescence staining system, wherein the 3D micro-fluidic chip comprises a 3D micro-fluidic detection system, a cell/tissue culture chamber and a liquid flow system, the 3D micro-fluidic chip is connected with the drug delivery system and the immunofluorescence staining system, and the immunofluorescence staining system comprises an image software system.
The cell/tissue culture chamber in the 3D micro-fluidic chip is communicated with the liquid flow system, the pipeline connected with the cell/tissue culture chamber is millimeter-sized, and a micro valve is introduced into the 3D micro-fluidic chip, so that automatic planting of tumor tissues can be realized in a liquid flow mode of the liquid flow system, the micro valve plays a role in controlling the flow of the liquid flow system, adjacent cell/tissue culture chambers are not affected when the tumor samples are cultured and detected, and the drug sensitivity detection precision of the tumor samples is improved.
The 3D micro-fluidic chip adopts an internationally universal polydimethylsiloxane material to construct a three-layer superposition structure, so that a tumor sample can be in a similar internal liquid flow system, and subsequent drug administration and detection are facilitated.
The tumor samples can be classified according to the age of the patient, the selected tumor samples are not treated by chemotherapy or other medicaments, and the same tumor sample is subjected to multipoint sampling, so that the accuracy of drug sensitivity detection of the tumor samples is improved, and the sporadic occurrence during detection is avoided.
The 3D microfluidic detection system can realize automatic cutting and automatic loading and loading of tumor samples, the tumor samples are automatically cut by the 3D microfluidic detection system to obtain micro tissue blocks with the sizes of (1 x0.5 mm), and then the tissue blocks are automatically loaded and loaded into a cell/tissue culture chamber at the bottom layer of the 3D microfluidic chip for culture, so that the follow-up observation of the growth condition of the tumor samples in the 3D microfluidic chip is facilitated.
The drug delivery system comprises drug treatment, wherein the drug treatment carries out combination classification on conventional chemotherapy scheme drugs, the drug treatment is sequentially carried out on tumor samples, meanwhile, the drug dosage can refer to normal clinical treatment dosage, the normal clinical treatment dosage can be ensured to inhibit the tumor in the subsequent treatment process of the tumor, and meanwhile, a non-drug adding group is arranged to detect the number of living cells and dead cells.
The immunofluorescence staining system can be used for marking living cells in a tumor sample, so that the cell quantity in the original tumor sample is compared, the dead cell quantity in the tumor sample can be obtained, and the dynamic inhibition rate of the used tumor drug to the tumor is detected.
The immunofluorescence staining system comprises an image software system, a marking image of living cells in a tumor sample can be recorded through an image detection system and presented through an image display system, the number of living cells of tumor tissues and the dynamic inhibition rate of tumor drugs on tumors are obtained by observing the staining condition of the immunofluorescence staining system on the tumor sample and the fluorescence staining depth, the fluorescence staining depth represents the fluorescence intensity and the fluorescence intensity represents the survival state of the living cells in the tumor sample, and therefore, staff can observe and record the growth condition of the cells of the tumor sample conveniently.
The workflow of the drug sensitive detection system is as follows:
s1, collecting tumor samples of surgical excision or biopsy in a tumor patient, wherein the tumor samples can be classified according to the age of the patient, the selected tumor samples are not treated by chemotherapy or other medicaments, multipoint sampling is carried out on the same tumor sample, the accuracy of drug sensitivity detection of the tumor samples is improved, and sporadic occurrence during detection is avoided;
s2, automatically cutting and loading a tumor sample through a 3D micro-fluidic detection system, automatically cutting the tumor sample through the 3D micro-fluidic detection system to obtain a micro tissue block with the size of (1 x0.5 mm), automatically loading and loading the tissue block into a bottom cell/tissue culture chamber of the 3D micro-fluidic chip for culture, and then carrying out drug administration on the 3D micro-fluidic chip through a drug administration system, wherein drug administration is required to carry out drug treatment, the drug treatment carries out combination classification on the conventional chemotherapy scheme drugs, the tumor sample is sequentially subjected to drug administration treatment, and meanwhile, the drug dosage can refer to normal clinical treatment dosage, so that in the follow-up treatment process of tumors, the normal clinical treatment dosage can realize tumor inhibition, and meanwhile, a non-drug administration group is arranged to detect the number of living cells and dead cells;
s3, marking living cells in the tumor sample through an immunofluorescence staining system, recording a marked image of the living cells in the tumor sample through an image detection system in the immunofluorescence staining system, and displaying through an image display system, and obtaining the number of the living cells of the tumor tissue and the dynamic inhibition rate of a tumor drug to the tumor by observing the staining condition of the immunofluorescence staining system on the tumor sample and the fluorescence staining depth, wherein the fluorescence staining depth represents the fluorescence intensity and the fluorescence intensity represents the survival state of the living cells in the tumor sample, so that the staff can observe and record the growth condition of the cells of the tumor sample conveniently;
s4, analyzing according to data presented by an immunofluorescence staining system, setting the inhibition rate of a medicine sieve for 3 days as a main end point of a clinical test, drawing a dose response curve according to the inhibition rate among different groups (age, histological typing and pre-operation stage), scoring according to the area under the curve AUC (the dose which leads to the reduction of the total surviving cell fraction by more than or equal to 35%), indicating that tumor tissues are more sensitive to a therapeutic medicine, classifying the tumor tissues into quick response, having response or no response according to the AUC value, comparing the drug sensitivity detection result with the experience of a clinician, checking whether the detection result is consistent, and judging the authenticity of the drug sensitivity detection result.
Although the present invention has been described with reference to the foregoing embodiments, it will be apparent to those skilled in the art that modifications may be made to the embodiments described, or equivalents may be substituted for elements thereof, and any modifications, equivalents, improvements and changes may be made without departing from the spirit and principles of the present invention.
Claims (9)
1. A drug sensitive detection system convenient for recording the growth condition of tumor cells comprises a tumor sample, a 3D microfluidic chip, a drug delivery system and an immunofluorescence staining system, and is characterized in that: the 3D microfluidic chip comprises a 3D microfluidic detection system, a cell/tissue culture chamber and a liquid flow system, wherein the 3D microfluidic chip is connected with a drug delivery system and an immunofluorescence staining system, and the immunofluorescence staining system comprises an image software system.
2. A drug sensitive assay system for facilitating the recording of the growth of tumor cells according to claim 1, wherein: the cell/tissue culture chamber in the 3D microfluidic chip is communicated with the liquid flow system, the pipeline connected with the cell/tissue culture chamber is millimeter-sized, a micro valve is introduced into the 3D microfluidic chip, automatic planting of tumor tissues can be realized through a liquid flow mode of the liquid flow system, the micro valve plays a role in controlling flow of the liquid flow system, adjacent cell/tissue culture chambers are not affected when culture detection is carried out on tumor samples, and the drug sensitivity detection precision of the tumor samples is improved.
3. A drug sensitive assay system for facilitating the recording of the growth of tumor cells according to claim 1, wherein: the 3D microfluidic chip adopts an international general polydimethylsiloxane material to construct a three-layer superposition structure, so that a tumor sample can be ensured to be in a liquid flow system similar to that in vivo, and subsequent drug administration and detection are facilitated.
4. A drug sensitive assay system for facilitating the recording of the growth of tumor cells according to claim 1, wherein: the tumor samples can be classified according to the ages of patients, the selected tumor samples are not treated by chemotherapy or other medicaments, and the same tumor samples are sampled at multiple points, so that the accuracy of drug sensitivity detection of the tumor samples is improved, and the sporadic occurrence during detection is avoided.
5. A drug sensitive assay system for facilitating the recording of the growth of tumor cells according to claim 1, wherein: the 3D microfluidic detection system can realize automatic cutting and automatic loading and loading of tumor samples, the tumor samples are automatically cut by the 3D microfluidic detection system to obtain micro tissue blocks with the sizes of (1 x0.5 mm), and then the tissue blocks are automatically loaded and loaded to a cell/tissue culture chamber at the bottom layer of the 3D microfluidic chip for culture, so that the follow-up observation of the growth condition of the tumor samples in the 3D microfluidic chip is facilitated.
6. A drug sensitive assay system for facilitating the recording of the growth of tumor cells according to claim 1, wherein: the drug delivery system comprises drug treatment, wherein the drug treatment carries out combination classification on the drugs of a conventional chemotherapy scheme, the drug treatment is sequentially carried out on tumor samples, meanwhile, the drug dosage can refer to the normal clinical treatment dosage, the normal clinical treatment dosage can be ensured to inhibit the tumor in the subsequent treatment process of the tumor, and meanwhile, a non-drug adding group is arranged to detect the number of living cells and dead cells.
7. A drug sensitive assay system for facilitating the recording of the growth of tumor cells according to claim 1, wherein: the immunofluorescence staining system can be used for marking living cells in a tumor sample, so that the cell quantity in an original tumor sample is compared, the dead cell quantity in the tumor sample can be obtained, and the dynamic inhibition rate of the used tumor drug to the tumor is detected.
8. A drug sensitive assay system for facilitating the recording of the growth of tumor cells according to claim 1, wherein: the immunofluorescence staining system comprises an image software system, a marking image of living cells in a tumor sample can be recorded through an image detection system and presented through an image display system, the number of living cells of tumor tissues and the dynamic inhibition rate of tumor drugs on tumors are obtained by observing the staining condition of the immunofluorescence staining system on the tumor sample and the fluorescence staining depth, the fluorescence staining depth represents the fluorescence intensity and the fluorescence intensity represents the survival state of the living cells in the tumor sample, and therefore, staff can observe and record the growth condition of the cells of the tumor sample conveniently.
9. A drug sensitive assay system for facilitating the recording of the growth of tumor cells according to claim 1, wherein: the workflow of the drug sensitive detection system is as follows:
s1, collecting tumor samples of surgical excision or biopsy in a tumor patient, wherein the tumor samples can be classified according to the age of the patient, the selected tumor samples are not treated by chemotherapy or other medicaments, multipoint sampling is carried out on the same tumor sample, the accuracy of drug sensitivity detection of the tumor samples is improved, and sporadic occurrence during detection is avoided;
s2, automatically cutting and loading a tumor sample through a 3D micro-fluidic detection system, automatically cutting the tumor sample through the 3D micro-fluidic detection system to obtain a micro tissue block with the size of (1 x0.5 mm), automatically loading and loading the tissue block into a bottom cell/tissue culture chamber of the 3D micro-fluidic chip for culture, and then carrying out drug administration on the 3D micro-fluidic chip through a drug administration system, wherein drug administration is required to carry out drug treatment, the drug treatment carries out combination classification on the conventional chemotherapy scheme drugs, the tumor sample is sequentially subjected to drug administration treatment, and meanwhile, the drug dosage can refer to normal clinical treatment dosage, so that in the follow-up treatment process of tumors, the normal clinical treatment dosage can realize tumor inhibition, and meanwhile, a non-drug administration group is arranged to detect the number of living cells and dead cells;
s3, marking living cells in the tumor sample through an immunofluorescence staining system, recording a marked image of the living cells in the tumor sample through an image detection system in the immunofluorescence staining system, and displaying through an image display system, and obtaining the number of the living cells of the tumor tissue and the dynamic inhibition rate of a tumor drug to the tumor by observing the staining condition of the immunofluorescence staining system on the tumor sample and the fluorescence staining depth, wherein the fluorescence staining depth represents the fluorescence intensity and the fluorescence intensity represents the survival state of the living cells in the tumor sample, so that the staff can observe and record the growth condition of the cells of the tumor sample conveniently;
s4, analyzing according to data presented by an immunofluorescence staining system, setting the inhibition rate of a medicine sieve for 3 days as a main end point of a clinical test, drawing a dose response curve according to the inhibition rate among different groups (age, histological typing and pre-operation stage), scoring according to the area under the curve AUC (the dose which leads to the reduction of the total surviving cell fraction by more than or equal to 35%), indicating that tumor tissues are more sensitive to a therapeutic medicine, classifying the tumor tissues into quick response, having response or no response according to the AUC value, comparing the drug sensitivity detection result with the experience of a clinician, checking whether the detection result is consistent, and judging the authenticity of the drug sensitivity detection result.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310315431.6A CN116539572A (en) | 2023-03-28 | 2023-03-28 | Drug sensitive detection system convenient for recording growth condition of tumor cells |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310315431.6A CN116539572A (en) | 2023-03-28 | 2023-03-28 | Drug sensitive detection system convenient for recording growth condition of tumor cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116539572A true CN116539572A (en) | 2023-08-04 |
Family
ID=87453140
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310315431.6A Pending CN116539572A (en) | 2023-03-28 | 2023-03-28 | Drug sensitive detection system convenient for recording growth condition of tumor cells |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116539572A (en) |
-
2023
- 2023-03-28 CN CN202310315431.6A patent/CN116539572A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0138833B1 (en) | Cell viability assay methods and apparatus | |
| ES2376422T3 (en) | METHOD AND QUANTIFICATION TEST TO DETERMINE THE STATE C-KIT / SCF / PAKT. | |
| KR20100115341A (en) | Improved methods and devices for cellular analysis | |
| US5356793A (en) | Method for testing the sensitivity of anticancer drug | |
| CN105850981B (en) | The method for freezing tumor tissues | |
| Le et al. | Comparison of the comet assay and the oxygen microelectrode for measuring tumor oxygenation in head-and-neck cancer patients | |
| Smolle et al. | Vascular architecture of melanocytic skin tumors: a quantitative immunohistochemical study using automated image analysis | |
| Klofas et al. | Instrument gauge and type in uveal melanoma fine needle biopsy: implications for diagnostic yield and molecular prognostication | |
| Cavarzerani et al. | 3D dynamic cultures of HGSOC organoids to model innovative and standard therapies | |
| Caspersson et al. | Cytochemical changes in the nucleus during tumour development | |
| CN116539572A (en) | Drug sensitive detection system convenient for recording growth condition of tumor cells | |
| CN107058456A (en) | A kind of circulating tumor cell 3D susceptibility test methods | |
| CN107144695B (en) | Application of the Arl13b albumen in cancer diagnosis | |
| CN114032277B (en) | Method for detecting drug sensitivity of tumor organoid based on staining method | |
| CN107502650A (en) | A kind of blood in vitro culture antineoplastic susceptibility detection method | |
| CN114380786A (en) | Aminopeptidase activated chemiluminescent probe and application thereof in living body detection and surgical navigation of malignant tumors | |
| Li et al. | Multi-slice spiral CT evaluation of breast cancer chemotherapy and correlation between CT results and breast cancerspecific gene 1 | |
| JPH03285696A (en) | Method for testing susceptivility of carcinostatic agent | |
| CN111896725A (en) | Accurate and personalized medicine treatment method for tumors and application | |
| KR102503115B1 (en) | Method of pre-processing body fluid sample and method of providing patient-specific anticancer drug information using the pre-processed body fluid sample | |
| CN112980690B (en) | PDX model incubation device and anti-tumor drug screening method | |
| WO2015110938A1 (en) | Device and method for testing a material response to a compound | |
| CN108929911A (en) | A kind of system using low depth genome sequencing detection cancer return | |
| CN109744199A (en) | A kind of tumour cell heterograft zebra fish model, its construction method and application | |
| Cheung et al. | Detection of neuroblastoma in bone marrow by immunocytology: is a single marrow aspirate adequate? |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |